<DOC>
	<DOCNO>NCT01358578</DOCNO>
	<brief_summary>This study ass safety efficacy secukinumab compare placebo etanercept patient moderate severe , chronic , plaque-type psoriasis .</brief_summary>
	<brief_title>Safety Efficacy Secukinumab Compared Etanercept Subjects With Moderate Severe , Chronic Plaque-Type Psoriasis</brief_title>
	<detailed_description />
	<mesh_term>Psoriasis</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<mesh_term>Etanercept</mesh_term>
	<criteria>Subjects chronic , plaquetype psoriasis least 6 month Must moderate severe psoriasis base PASI great 12 , IGA great 3 , great 10 % body surface area Must inadequately control prior treatment ( topicals , phototherapy , and/or systemic therapy ) Forms psoriasis chronic , plaquetype ( pustular , erythrodermic guttate psoriasis ) Drug induce psoriasis Use psoriasis treatment study Prior use etanercept Prior use secukinumab drug target IL17 ( interleukin 17 ) IL17 receptor Pregnant lactate woman ; woman agree use contraception study 16 week stop treatment Significant medical problem uncontrolled high blood pressure , congestive heart failure , etc . History ongoing , chronic recurrent infection evidence tuberculosis Allergy rubber latex Other protocoldefined inclusion/exclusion criterion may apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2016</verification_date>
	<keyword>Psoriasis ,</keyword>
	<keyword>inflammatory skin disease ,</keyword>
	<keyword>scaly patch</keyword>
	<keyword>Psoriasis</keyword>
	<keyword>inflammatory skin disease</keyword>
</DOC>